At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
cyclosporine 0.05% ophthalmic emulsion +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
In Brief
A Phase 4 clinical trial evaluating cyclosporine 0.05% ophthalmic emulsion and carboxymethylcellulose-based lubricant eye drops for Dry Eye Syndromes. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (Restasis®) in patients with dry eye disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedApr 2014
Primary CompletionSep 2014
TodayJul 2026
First PostedApr 24, 2014
Enrollment StartApr 3, 2014
Primary CompletionSep 23, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.2 years ago
Interventions
cyclosporine 0.05% ophthalmic emulsiondrug
Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
carboxymethylcellulose-based lubricant eye dropsdrug
Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.